Paul Hudson, CEO of Sanofi, has been driving an all-encompassing effort to use AI to reshape the way the company ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

Sanofi CEO Paul Hudson speaks during the Competing In The Global Marketplace: Strategies for Growth panel, at the Fortune Global Forum on Nov. 11, 2024 in New York City. ·Fortune·Jemal Countess ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

Paul Hudson, CEO of Sanofi, works in a volatile business. The pharma sector has been very profitable for many decades, and its weight in the economy has grown steadily. But for individual ...

French pharmaceutical giant Sanofi reported a sharp increase in second-quarter profit on Thursday, driven by higher net sales ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

PARIS — Sanofi’s Chief Executive Paul Hudson is dipping into coffers filled by recent disposals to buy U.S.-based Principia Biopharma Inc for $3.7 billion as he fills his medicine cabinet with ...

MARCY-L-E’TOILE — Sanofi’s Chief Executive Paul Hudson on Tuesday sought to set aside tensions with the French government and said the drugmaker was committed to helping France build up its healthcare ...

Sanofi said it would acquire all outstanding shares of Translate Bio for US$38 a share in cash, representing a total equity value of about US$3.2-billion for Translate Bio.